UTHR stock news · United Therapeutics Corporation
Get alerts for UTHR
Follow United Therapeutics Corporation (UTHR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for UTHRAn insider at United Therapeutics sold $5,650,415 worth of stock recently.
NeutralUnited Therapeutics reported an insider share sale in a routine filing. The report gives no reason for it, so it does not change the company's business outlook.
United Therapeutics Corp is starting a $2.0 billion plan to buy back its own shares.
Good for UTHRUnited Therapeutics authorized up to $2.0 billion to buy its own shares over 1 year. This creates a way to return cash, though no purchases are reported yet.
Liquidia has ended a tough battle with United Therapeutics by agreeing to a $380.7 million settlement.
Good for UTHRUnited Therapeutics is set to receive $380.7 million, and the settlement ends 6 disputes. Liquidia can still sell YUTREPIA for PAH, but the payment and end to the legal fights favor United Therapeutics.
Stock futures for the S&P 500 and Dow Jones are up as people wait for the September inflation report, with ASML, GME, and UNH getting attention.
NeutralUnited Therapeutics reached a settlement with Liquidia that ends all pending lawsuits. The article gives no terms or company-specific cost or benefit, so it does not show a clear business change for UTHR.
Liquidia's stock keeps dropping after a U.S. court decision in a patent fight.
Good for UTHRThe court upheld 2 United Therapeutics patent claims and found Liquidia infringed them over Yutrepia. Four other claims were invalidated, and remedies remain undecided, but the ruling strengthens United Therapeutics’ case against a rival product.
United Therapeutics' stock went up after a court ruled in its favor against Liquidia over a patent issue.
Good for UTHRUnited Therapeutics won a patent ruling against Liquidia, strengthening its position in inhaled lung treatment. The FDA has not yet withdrawn approval of the rival drug.
Progress Software, Nft, and other major stocks dropped in value before the market opened on Thursday.
Good for UTHRA court upheld claims in a patent asserted by United Therapeutics and found Liquidia infringed them. That supports United Therapeutics' patent position.
Liquidia (LQDA) stock is getting attention after a court said it broke two patents.
Good for UTHRUnited Therapeutics won on 2 patent claims and asked for an order restricting Yutrepia. Other asserted claims were invalid, making this a partial win, but the court's ruling supports its effort.
Liquidia Corp: Other Events (LQDA)
NeutralUnited Therapeutics is identified as the company that filed the case over its patent and Liquidia's YUTREPIA. The filing gives no court ruling or case outcome, so it does not show a change in United Therapeutics' outlook.
Big trades in 10 health care stocks happened today.
NeutralUnited Therapeutics had a put trade labeled neutral. The report gives no company news, so it does not change the company's outlook.